Compare KPTI & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | CMCM |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 195.2M |
| IPO Year | 2013 | 2014 |
| Metric | KPTI | CMCM |
|---|---|---|
| Price | $7.41 | $6.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.17 | N/A |
| AVG Volume (30 Days) | ★ 219.5K | 40.5K |
| Earning Date | 11-03-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $142,530,000.00 | ★ $151,517,306.00 |
| Revenue This Year | $3.82 | $14.27 |
| Revenue Next Year | N/A | $39.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 46.34 |
| 52 Week Low | $3.51 | $3.28 |
| 52 Week High | $12.45 | $9.44 |
| Indicator | KPTI | CMCM |
|---|---|---|
| Relative Strength Index (RSI) | 65.63 | 41.38 |
| Support Level | $5.99 | $6.43 |
| Resistance Level | $7.70 | $6.98 |
| Average True Range (ATR) | 0.54 | 0.28 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 86.03 | 5.94 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.